Neither peptide therapy nor traditional TRT provides overnight transformation, but both can deliver significant improvements when properly implemented
For people with type 2 diabetes, it's worth noting that rapid improvement in glycaemic control with GLP-1 receptor agonists like semaglutide has been associated with worsening of diabetic retinopathy in some cases, requiring appropriate monitoring
as your future business partner is an easy and reasonable choice if you value safe goods, excellent results, and honesty.
For those beginning either drug, monitoring food intake, body weight, and activity levels can indicate whats working or needs adjustment
2025 saw a bidding war between Pfizer and Novo Nordisk for Metsera and its portfolio of obesity agents, which was ultimately won by Pfizer for up to $10 billion